GlassScriptPhysician profile
Chad R Stencel
NPI 1386056208
$3,789.34
in general payments reported to CMS, 2019-2025
43 companies · $899 in 2025
The $899 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $116 · 2021: $216 · 2022: $458 · 2023: $805 · 2024: $861 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $718.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $444.43 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $285.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $268.25 | 2019-2025 | |
| Abbott Laboratories | $258.57 | 2022-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $233.16 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $157.71 | 2019-2025 | Bexsero, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $146.13 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $135.58 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $126.92 | 2019-2023 | Breztri, Farxiga |
| Astellas Pharma US INC | $97.40 | 2020-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $76.80 | 2022-2023 | Gattex, Vpriv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.84 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.56 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $46.42 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Stencel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.